Kolabtreeを選ぶ理由
開始はすばやく簡単です。初期費用はかかりません。
サービス依頼と専門家への見積依頼は無料です。
Kolabtree の作業範囲に同意する前に、専門家と要件を詳しく相談できます。
専門家と直接連携し、必要な成果を正しく得られます。
専門家を採用したらプロジェクトに資金を入れ、作業完了後に成果物を承認できます。
この専門家をプロジェクトに採用したいですか? 見積もりを依頼 無料で。
プロフィール詳細
プロジェクトを作成
★★★★★
☆☆☆☆☆
Soumyajit M.に依頼
United Kingdom

Translational Immunology & Cancer Immunotherapy Scientist | Expert in Organoid–Immune Co-Culture & High-Content Imaging

プロフィール概要
専門分野
サービス
Writing Medical Writing, Technical Writing, Creative Writing, Newswriting, General Proofreading & Editing
Research Market Research, Technology Scouting, Fact Checking, Gap Analysis, Scientific and Technical Research, Systematic Literature Review
Consulting Healthcare Consulting, Operations Consulting, Scientific and Technical Consulting, Regulatory Consulting
Data & AI Image Analysis, Data Visualization, Data Processing
Product Development Recipe Development, Product Evaluation, Concept Development, Reverse Engineering
職務経験

The University of Birmingham

- 現在

Senior Research Technician II

The University of Birmingham

11月 2025 - 現在

Reserach Technician

University of Birmingham

10月 2022 - 6月 2023

学歴

MSc in Biotechnology (Biotechnology)

University of Glasgow

9月 2021 - 9月 2022

B.Tech in Biotechnology (Biotechnology)

Techno India University

8月 2016 - 8月 2020

認定資格
  • 認定資格の詳細は未入力です。
出版物
JOURNAL ARTICLE
Soumyajit Mallick, Sandra Margielewska-Davies, Wayne Croft, Hayden Pearce, Natalie To, Fouzia Zayou, Falguni Meghrajani, Jing Zhang, Claudia M. A. Pinna, Laura Bills, et al. (2026). IGF2BP3-mediated regulation of the RNA isoform and modification landscape in pancreatic cancer . Oncogene.
IGF2BP3-mediated regulation of the RNA isoform and modification landscape in pancreatic cancer @article{fe99695401294a18ac350059fc5bab82, title = "IGF2BP3-mediated regulation of the RNA isoform and modification landscape in pancreatic cancer", abstract = "The incidence of pancreatic ductal adenocarcinoma (PDAC) is increasing but clinical outcomes remain poor and new treatments are required. IGF2BP3 is an oncofetal m6A-reading RNA regulatory protein whose expression is commonly observed in PDAC and which may represent an important therapeutic target. IGF2BP3 protein is expressed in >95\% of primary tumours whilst RNA expression ranges from 3 to 3000-fold above normal epithelium. siRNA knockdown reveals IGF2BP3 to strongly support expression of gene programs related to DNA replication, cell cycle and apoptosis, TNF signalling and epithelial-mesenchymal transition. Direct sequencing of native RNA further reveals IGF2BP3-mediated enhancement of 863 RNA isoforms with suppression of 389 isoforms. m6A, m5C and pseudouridine (ψ) RNA modifications were seen in 97\% of transcripts within the PDAC transcriptome and enriched within MYC gene targets. IGF2BP3 regulated the pattern of RNA modification with a substantial impact on m5C modifications of miRNA and scRNA, and genes associated with regulation of TNF signalling. Knockdown of IGF2BP3 expression in primary tumour organoid cultures suppressed proliferation and elicited apoptosis, indicating a critical requirement for IGF2BP3 within malignant stem cells. These data show that IGF2BP3 is expressed consistently in PDAC, plays a dominant role in regulation of RNA splicing and modification, and supports cancer stem cell proliferation and survival. IGF2BP3 therefore occupies a critical position within the RNA regulon of PDAC and represents an important therapeutic target in this tumour of unmet need.", author = "Sandra Margielewska-Davies and Wayne Croft and Hayden Pearce and Natalie To and Fouzia Zayou and Falguni Meghrajani and Jing Zhang and Pinna, \{Claudia M A\} and Laura Bills and Beggs, \{Andrew D\} and Soumyajit Mallick and Powell-Brett, \{Sarah F\} and Rachel Brown and Jianmin Zuo and Roberts, \{Keith J.\} and Paul Moss", year = "2026", month = aug, day = "7", doi = "10.1038/s41388-026-03933-3", language = "English", journal = "Oncogene", issn = "0950-9232", publisher = "Nature Publishing Group", } . Oncogene.
Endemic penetrance of SARS-CoV-2 has impacted marginally on immunity to spike protein of human coronaviruses @article{5cc4b73764034476b134e59c2a1e5943, title = "Endemic penetrance of SARS-CoV-2 has impacted marginally on immunity to spike protein of human coronaviruses", abstract = "SARS-CoV-2 has emerged as the 5th endemic coronavirus and immunological cross protection between coronaviruses will influence their infectivity and clinical impact. We determined adaptive immunity against the spike protein of each human coronavirus during the course of the COVID-19 pandemic. A characteristic pattern of HCoV immunodominance, dominated by OC43 and 229E, was apparent prior to SARS-CoV-2 and was largely unaffected by SARS-CoV-2 infection, which itself elicited moderate antibody titre. Vaccination or hybrid immunity elicited supraphysiological levels of coronavirus-specific antibodies, only a proportion of which was cross-reactive with SARS-CoV-2 spike indicating substantial backboosting of HCoV-specific responses. SARS-CoV-2 vaccination focused antibody responses against the S1 domain of SARS-CoV-2 spike whilst T cell responses recognised peptides equivalently across S1 and S2. Coronavirus-specific T cells exhibited strong production of IFN-γ, IL-2 and CXCL8. In summary, the entry of SARS-CoV-2 into its ecological niche has impacted marginally on relative immunity against other human coronaviruses although vaccination provides a modest antibody increment which is unlikely to be maintained. Further, although SARS-CoV-2 vaccination elicits spike-specific adaptive immune responses that are focused against the S1 domain, thereby favouring neutralising antibodies, the natural history of HCoV immunity indicates that adaptive responses may transition towards S2 recognition across the life course.", author = "Tara Lancaster and Gokhan Tut and Panagiota Sylla and David Bone and Christopher Bentley and Eliska Spalkova and Azar Jadir and Rachel Bruton and Katie Spencer and Soumyajit Mallick and Ahmed Elzaidi and Siobhan Plass and Nayandeep Kaur and Megan Butler and Samuel Hulme and Dowell, \{Alexander C.\} and Maria Krutikov and Oliver Stirrup and Borscha Azmi and Andrew Hayward and Andrew Copas and Laura Shallcross and Paul Moss", year = "2026", month = feb, day = "9", doi = "10.1038/s42003-025-09474-x", language = "English", volume = "9", journal = "Communications Biology", issn = "2399-3642", publisher = "Nature Publishing Group", number = "1", } . Communications Biology.
Soumyajit Mallick, Thomas Roberts, Grace Uwenedi, Rachel Bruton, Graham McIlroy, Sarah Damery, Panagiota Sylla, Nicola Logan, Sam Scott, May Lau, et al. (2024). Enhancement of Omicron-specific immune responses following bivalent COVID-19 booster vaccination in patients with chronic lymphocytic leukaemia . Blood Cancer Journal.
Soumyajit Mallick, Helen Parry, Rachel Bruton, Grace Uwenedi, Thomas Roberts, Panagiota Sylla, Jonathan Cook, Ahmed Elzaidi, May Lau, Tamsin Drury, et al. (2024). Robust generation of neutralising antibodies against Omicron variants following bivalent mRNA booster vaccine in elderly people aged >80 years . Journal of Infection.